Is "Ozempic Microdosing" Real? The Actual Dose Chart, Cost, and Where It's Sold

Is there actually such a thing as "Ozempic microdosing"?

No — and the correction matters before anything else here. Ozempic is Novo Nordisk's trademarked, FDA-approved brand name for a specific semaglutide injection pen, approved in 2017 for adults with type 2 diabetes. It ships in exactly one device, with a fixed, FDA-reviewed dose ladder that tops out at 2mg weekly. Novo Nordisk has never manufactured, sold, or marketed a smaller "microdose" version of that pen, and no pharmacy can legally compound a copy of it and call it Ozempic — a trademark protects the whole finished product, not just the molecule inside it.

So when a telehealth ad, a Reddit thread, or a wellness influencer says "Ozempic microdosing," they're almost always describing something else: compounded semaglutide, prepared by a licensed pharmacy at a smaller amount than any FDA-approved dose, sold under a platform's own branding rather than Novo Nordisk's. Novo Nordisk has been aggressive about defending that line — the company has filed well over 100 lawsuits against compounders, med spas, and telehealth sellers across dozens of states, and in April 2025 won a permanent injunction against one compounding pharmacy that had marketed knockoff drugs using the Ozempic name, with court-ordered disclosures telling patients the products were never FDA-reviewed. That's the practical reason no legitimate seller advertises "Ozempic microdosing" as a literal product name — the ones that do are the ones worth being wary of.

• Ozempic = Novo Nordisk's trademarked, FDA-approved semaglutide pen for type 2 diabetes, with one fixed dose ladder and no manufacturer microdose variant.
• "Ozempic microdosing" as sold online = compounded semaglutide, a different, non-branded product made by a pharmacy, not Novo Nordisk.
• For the full legal picture on compounded semaglutide generally — not just the microdosing angle — see compounded Ozempic.

What does an "Ozempic microdosing chart" actually show — the real FDA dose ladder

If you're picturing a chart with tiny fractional doses below what your doctor prescribes, Ozempic's actual label doesn't have one. Its escalation schedule is short, fixed, and climbs upward, not down — designed to ease GI side effects on the way up to an effective diabetes dose, not to stay small indefinitely.

Notice what's missing: anything below 0.25mg. That first step already is the lowest dose Ozempic's label recognizes, and it's explicitly a temporary initiation dose, not a place the label expects anyone to stay. A genuine "Ozempic microdosing chart," in the sense of a smaller, ongoing FDA dose, doesn't exist because the label doesn't go there. For the complete ladder including the newer oral tablet and missed-dose rules, see the semaglutide dosage guide.

So where is "Ozempic microdosing" actually sold?

Nowhere, under that name, from a legitimate seller — but a small number of telehealth platforms sell a genuinely lower-dose compounded semaglutide product, just not one connected to Ozempic. Henry Meds, Mochi Health, Noom, and Fridays each sell a version, priced above, using compounded semaglutide rather than the branded pen. That's the same molecule Ozempic contains, prepared differently, by a pharmacy rather than Novo Nordisk, at a dose below anything the FDA label covers.

This page keeps that comparison short on purpose, since the deeper research on these four platforms — dosing philosophy, contract length, what happens if a provider exits the market — already lives on a dedicated page. For the full provider-by-provider breakdown, see semaglutide microdosing.

What does it actually cost — compounded microdosing vs. real Ozempic

This is where the gap gets concrete. Ozempic's retail list price runs roughly $1,028 to $1,100 a month with no savings applied — call it $12,336 to $13,200 a year — and Novo Nordisk has signaled further list-price moves are possible, so treat that figure as one to keep checking rather than fixed. Commercially insured patients with a documented type 2 diabetes diagnosis can use the NovoCare savings card to bring that down to around $25 to $50 a month, by far the cheapest path if you qualify. Without insurance, Novo Nordisk's own self-pay program runs an introductory rate before settling at $349 a month at the 1mg maintenance dose, or $499 a month at 2mg — about $4,188 to $5,988 a year. For the full pathway breakdown, see Ozempic cost.

Compounded semaglutide microdosing, by contrast, runs about $150 to $249 a month across the four platforms above (Noom's intro rate starts even lower, at $79) — roughly $1,800 to $2,990 a year at steady state, well under half of NovoCare self-pay, and nowhere near retail. What you're paying less for is real: a smaller amount of active drug, a compounded rather than FDA-reviewed formulation, and — for at least three of the four platforms — a program built around weight management rather than a T2D indication. It isn't a cheaper way to buy the same Ozempic pen; it's a genuinely different, lower-dose product at a genuinely lower price.

Can you just dial your own Ozempic pen down instead?

This question comes up because of how the Ozempic pen actually works, and it's worth answering mechanically rather than just discouraging it. Ozempic ships in Novo Nordisk's FlexTouch device, a multi-dose, dial-adjustable pen — you turn a dial to select your dose and press a button to inject, and one pen lasts several weeks depending on strength. That's genuinely different from Wegovy, which comes in a single-dose, pre-set autoinjector with no dial at all, built that way specifically so patients can't select a dose themselves.

But the dial only moves between the doses the label actually supports — 0.25mg, 0.5mg, 1mg, and 2mg on the newer pens. There's no setting below 0.25mg to select; the device's lowest increment is already the label's lowest step. The closest thing to "microdosing" a real Ozempic pen is simply staying on the 0.25mg initiation dose past the four weeks it's meant to cover, rather than progressing as the label intends — an off-label choice about timing, not a manufactured lower dose. Splitting or repeatedly drawing extra from a pen not designed for it introduces contamination and dosing-accuracy risk that has nothing to do with getting a smaller number.

Is there real science behind a lower-than-labeled Ozempic dose?

The dose-response evidence behind Ozempic's own approval points the other direction. Novo Nordisk's SUSTAIN trial program, which supported Ozempic's type 2 diabetes indication, found that higher doses on the ladder — 1mg and 2mg — produced greater reductions in blood sugar than 0.5mg, not the reverse. That trial program was built around climbing the ladder for better glycemic control, not staying below its first rung. There's no completed clinical trial testing what happens if someone stays under Ozempic's 0.25mg starting dose long-term, for diabetes control or anything else.

The separate compounded-semaglutide products marketed as microdosing rest on a different, softer kind of evidence: a plausible mechanism (semaglutide's single-receptor GLP-1 action scales with dose), some self-reported tolerability data from the platforms selling it, and no completed trial specifically evaluating that low-dose approach. That's a real but thin evidence base — worth knowing whether your interest in this is Ozempic's diabetes indication specifically or the broader semaglutide-for-weight-management conversation, since the honest answer differs slightly for each.

Are side effects gentler at a lower dose — and does it still work?

Probably somewhat gentler, and this part does have a real basis: across the semaglutide trial data, GI side effects like nausea tend to cluster right after each dose increase and ease as the body adjusts, which is part of why Ozempic's own label builds in that slow four-week climb in the first place. A genuinely smaller, steadier dose — through a compounded microdose product — plausibly means less of that adjustment to go through. What's far less certain is effectiveness at that level. For diabetes control specifically, Ozempic's own trial data shows better blood sugar results at the higher, labeled doses, not the lower ones — so if glycemic control is your actual goal, staying meaningfully under 0.5mg works against the evidence, not with it.

Is this worth exploring if you're perimenopausal and already on Ozempic for prediabetes or insulin resistance?

If you landed on Ozempic specifically — not Wegovy, not a weight-loss-branded compounded plan — there's a decent chance a real prediabetes or type 2 diagnosis brought you here, and perimenopause has its own relationship to that: declining estrogen is linked to reduced insulin sensitivity in a lot of women, which is part of why blood sugar numbers can shift in your forties even without major lifestyle changes. That context matters for this specific question, because it changes what "microdosing" would even be trying to accomplish. A lower dose aimed at gentler side effects while you titrate up toward an effective diabetes dose is a reasonable conversation to have with your prescriber. A lower dose meant to stay there indefinitely, chasing a smaller number long-term, runs against what the SUSTAIN evidence actually shows for glycemic control.

If weight change alongside insulin resistance is also part of the picture, the fuller hormonal context is worth understanding on its own terms — see GLP-1 medications and menopause weight gain — and if a slower titration is genuinely the plan regardless of the reason, it's worth knowing that pacing more gradually also tends to be easier on muscle mass, which matters more once estrogen decline is already working against your lean mass on its own; that tradeoff is covered in GLP-1s and muscle loss in perimenopause.

How to tell a legitimate low-dose protocol from a DIY red flag

The line that matters isn't the number on the dose — it's who's managing it and what pharmacy is behind it. A legitimate low-dose or microdose protocol comes from a licensed prescriber, filled through a named 503A compounding pharmacy, with a dose your provider set and can adjust. A red flag looks different: a product literally marketed as "Ozempic microdosing" rather than compounded semaglutide, an unnamed pharmacy, or a seller pushing you toward splitting a real Ozempic pen yourself.

The FDA has already documented what goes wrong with the self-directed version. A July 2024 alert on compounded semaglutide dosing errors described patients accidentally injecting five to twenty times their intended dose after misreading units on a syringe, some requiring hospitalization. Compounded semaglutide's legal footing has also narrowed since the 2022–2024 shortage years that once made it available almost everywhere: the FDA declared the shortage resolved in February 2025, and what remains is a narrower 503A pathway built around a documented individual clinical need, not simply a lower price. If a seller can't name its compounding pharmacy or explain that pathway, that's the moment to walk away rather than adjust anything yourself.